Press releases
About Byondis
Driven to improve patients’ lives, Byondis is an independent, fully integrated biopharmaceutical research and development company creating innovative targeted medicines for cancer. The company is developing new biological entities (NBEs) with a focus on antibody-drug conjugates.
Byondis’ development portfolio leverages expertise in linker-drug (LD) technology, antibody-drug conjugation, and disease biology. Byondis’ fully integrated drug development capabilities cover all stages from pre-clinical and clinical R&D, production of clinical batches of the selected product candidates, and regulatory filings which are all done in-house.
The company has a dedicated team of more than 200 staff working in its state-of-the-art R&D and GMP manufacturing facilities in Nijmegen, the Netherlands.
R&D and Manufacturing
Fully integrated in-house R&D and Manufacturing from discovery to development to commercial supply.
Investors & Media
Byondis is an independent clinical stage fully integrated biopharmaceutical research and development company creating innovative targeted medicines for cancer. The company is developing new biological entities (NBEs) with a focus on antibody-drug conjugates and antibody-based therapeutics.
